Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
INVO FertilityIVF -8.37%35 Debt-to-EBITDA is -0.19 as of Mar. 2026. GuruFocus rates IVF with a GF Score™ of 35/100 and a GF Value™ of $128.62 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 469 Medical Devices & Instruments companies, INVO Fertility ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for INVO Fertility's Debt-to-EBITDA or its related term are showing as below:
IVF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.55 Med: -0.33 Max: -0.14
Current: -0.51
During the past 13 years, the highest Debt-to-EBITDA Ratio of INVO Fertility was -0.14. The lowest was -1.55. And the median was -0.33.
IVF's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs IVF: -0.51
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
INVO Fertility Debt-to-EBITDA Related Terms
INVO Fertility Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for INVO Fertility's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVF vs RMSL, ADMT, USAQ: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, INVO Fertility's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INVO Fertility Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, INVO Fertility's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where INVO Fertility's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
INVO Fertility (IVF) has a Debt-to-EBITDA of -0.19 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on INVO Fertility. According to the industry distribution chart, INVO Fertility ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is INVO Fertility's Debt-to-EBITDA too high?
INVO Fertility's current Debt-to-EBITDA is -0.19. Based on the distribution chart, INVO Fertility ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, INVO Fertility has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does INVO Fertility's Debt-to-EBITDA compare to RMSL and ADMT?
According to the Medical Devices & Instruments industry distribution chart, INVO Fertility ranks #999999 out of 469 companies for Debt-to-EBITDA. This places INVO Fertility in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on INVO Fertility. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INVO Fertility's current Debt-to-EBITDA is -0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INVO Fertility stock overvalued right now?
Based on GuruFocus' analysis, INVO Fertility (IVF) is currently considered Possible Value Trap. The stock's GF Value™ is $128.62, compared to a current price of $1.05 — trading 99.2% below its estimated fair value. The current Debt-to-EBITDA is -0.19. INVO Fertility's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For INVO Fertility (IVF), the current Debt-to-EBITDA is -0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INVO Fertility (IVF) Overvalued in 2026?
Based on GuruFocus' analysis, INVO Fertility stock appears to be undervalued.
The current stock price of $1.05 is trading 99.2% below its estimated GF Value™ of $128.62.
GuruFocus considers INVO Fertility to be Possible Value Trap.
Key valuation signals for IVF:
Debt-to-EBITDA: -0.19
GF Value™: $128.62 vs. price of $1.05 (99.2% below fair value)
No single metric tells the full story. See the IVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic and The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell.
35GF Score
Get the complete analysis for IVF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVF has been successfully added to your 
